Allocetra is named as an intervention in 3 current clinical trials in our Denmark, Israel, USA and Poland registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Enlivex Therapeutics Ltd (2). The most-studied condition is Primary Knee Osteoarthritis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716 · ClinicalTrials.gov ↗ · Primary Knee Osteoarthritis
|
Phase 2 | Recruiting | Enlivex Therapeutics Ltd | USA, Denmark, Poland |
|
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
NCT06748651 · ClinicalTrials.gov ↗ · Temporomandibular Joint Osteoarthritis
|
Phase 1 | Recruiting | Dr. Amit Druyan | Israel |
|
Study of Intra-articular Allocetra in Knee Osteoarthritis
NCT06233474 · ClinicalTrials.gov ↗ · Osteoarthritis, Knee
|
Phase 1/2 | Active, closed | Enlivex Therapeutics Ltd | Denmark, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Enlivex Therapeutics Ltd | 2 |
| Dr. Amit Druyan | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 2 | 1 |
| Clinical trials in Israel | 2 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Denmark, Israel, USA and Poland registers name Allocetra as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Denmark, 1 with sites in Israel, 1 with sites in USA and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Enlivex Therapeutics Ltd (2) and Dr. Amit Druyan (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Allocetra works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Allocetra works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Allocetra (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.